参芪扶正注射液治疗矽肺合并肺原性心脏

发布时间：2018-11-10 07:00

【摘要】：探讨参芪扶正注射液治疗矽肺合并肺原性心脏病、心力衰竭的疗效。将120例矽肺合并肺原性心脏病、心力衰竭患者按心功能级别分为治疗组和对照组,对照组采用常规治疗,治疗组在常规治疗基础上加用参芪扶正注射液,疗程均为15d。结果显示,治疗组与对照组比较,能明显改善病人的临床症状及心功能,总有效率分别为83.3%和58.3%,差异有统计学意义(P0.05)。提示,参芪扶正注射液治疗矽肺合并肺原性心脏病、心力衰竭安全有效。
[Abstract]:To investigate the effect of Shenqi Fuzheng injection on silicosis complicated with pulmonary heart disease and heart failure. 120 patients with silicosis complicated with pulmonary heart disease were divided into treatment group and control group according to heart function grade. The control group was treated with routine therapy, and the treatment group was treated with Shenqi Fuzheng injection on the basis of routine treatment. The course of treatment was 15 days. The results showed that compared with the control group, the treatment group could significantly improve the clinical symptoms and cardiac function, the total effective rate was 83.3% and 58.3% respectively, the difference was statistically significant (P0.05). It suggests that Shenqi Fuzheng injection is safe and effective in the treatment of silicosis complicated with pulmonary heart disease.
【作者单位】：河北宣化钢铁公司职工医院;
【分类号】：R135.2;R541.5;R541.6

【参考文献】